The Latest Cardiac and Vascular News
LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two cohorts, including myocardial protein expression and biomarkers measuring serum and cardiac structure and function, expected in the first half of 2024 NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) — LEXEO Therapeutics (LEXEO), […]
Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of Stockholders MIAMI, June 13, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced […]
SSi Mantra System now Clinically Validated in More Than 35 Different Surgical Procedures FORT LAUDERDALE, FL, June 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to […]
The study represents a significant breakthrough in understanding the potential for reversing and measuring epigenetic changes associated with coronary heart disease after therapeutic intervention June 13, 2023 09:01 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced the […]
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure WARRINGTON, Pa., June 12, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for […]
MIAMI–(BUSINESS WIRE)–Ambulero, Inc. is developing a first-in-class gene and cell therapy platform for treating serious vascular diseases and non-healing wounds where amputation is a care option. In support of this effort, the NHLBI CATALYZE program of the National Institutes of Health approved a second phase of funding for IND-enabling work […]
Acquisitions broaden Merit’s therapeutic platform with diverse dialysis product solutions and expand its access catheter offering Acquisitions projected to add approximately $30 million of revenue, on an annualized basis, in key strategic markets that leverage existing commercial footprint Merit re-affirms full-year 2023 financial guidance on stand-alone basis and updates full-year […]
GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a medical device company developing next-generation “super-bore” catheter technology to treat acute ischemic stroke, is pleased to announce the appointment of Hooman Hakami as the new Chair of the Board. This appointment reflects Perfuze’s commitment to bring devices to market that have the potential to transform the […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of May 31, 2023 (pursuant to Article L. 233-8 II of the […]
CARLSBAD, Calif., June 7, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities […]
